Validation of Procedures for Monitoring Crew Member Immune Function (Integrated Immune) will assess the clinical risks resulting from the adverse effects of space flight on the human immune system and will validate a flight-compatible immune monitoring strategy. To monitor changes in the immune system, researchers collect and analyze blood, urine and saliva samples from crewmembers before, during and after space flight.Principal Investigator(s)
Johnson Space Center, Human Research Program, Houston, TX, United States
National Aeronautics and Space Administration (NASA)Sponsoring Organization
Human Exploration and Operations Mission Directorate (HEOMD)ISS Expedition Duration:
October 2007 - September 2012
16,17,18,19/20,21/22,23/24,25/26,27/28,29/30,31/32Previous ISS Missions
Increment 16 was the first mission for Integrated Immune.
The Validation of Procedures for Monitoring Crewmember Immune Function (Integrated Immune) is designed to develop and validate an immune monitoring strategy consistent with operational flight requirements and constraints. There are no procedures currently in place to monitor immune function or its influence on crew health. Immune dysregulation has been demonstrated to occur during space flight, yet little in-flight immune data has been generated to assess this clinical problem. Integrated Immune assesses the clinical risks resulting from the adverse effects of space flight on the human immune system and will validate a flight-compatible immune monitoring strategy. Characterization of the clinical risk and the development of a monitoring strategy are necessary prerequisite activities prior to validating countermeasures.
Preflight, in-flight and postflight assessments are performed as part of the Integrated Immune investigation. The in-flight samples allow investigators to assess the distinction between legitimate in-flight alterations, and the physiological stresses of landing, which are believed to alter landing day assessments. The overall status of the immune system during flight (activation, deficiency, dysregulation) and the response of the immune system to specific latent virus reactivation, (known to occur during space flight) are thoroughly assessed.
Following completion of the investigation, the data will be evaluated to determine the optimal set of assays for routine monitoring of crewmember immune system function. It is intended that the determined set of relevant assays will be incorporated into the Clinical Status Evaluation (CSE) and utilized to monitor the effectiveness of human medical countermeasures related to immune function (exercise, medication, diet regulation-supplementation, immune modulators, etc.). In addition, the assays validated here have significant benefits for the routine monitoring of crewmember's immune system status with regard to diagnosis and prognosis of immune-related disease states.
The study will result in the validation of a monitoring strategy that allows the development of effective countermeasures, which when implemented, will safeguard the health of the crew during long-duration space missions.Earth Applications
The data collected during this investigation may lead to a greater understanding of how the immune system is affected by different factors from stress to the environment. This data could potentially be used to help develop new treatments and preventative measures for immune dysfunctions.
Preflight, each subject performs two sessions: one at L-180 (launch minus 180) days and another at L-45 days. Each session consists of a health survey, four liquid saliva collections (performed every other day), blood draw, 24-hour urine and dry book saliva sample collection occurring on the day between the second and third liquid saliva collection.
Postflight, each long duration subject performs two sessions: one at R+0 collecting four liquid saliva samples collected every other day starting on R+0 in conjunction with a blood draw and 24-hour urine collection. The second session occurs at R+30 days collecting four liquid saliva samples (performed every other day) with a blood draw and 24-hour urine collection occurring on the day between the second and third liquid saliva collections. Dry book saliva samples are collected on R+1 and R+30 days. A health survey is completed in conjunction with both post-flight sessions. Each short duration subject performs two post-flight sessions: one at R+0 collecting blood, 24-hour urine and dry saliva. The second is performed at R+14 collecting the same set of measurements as obtained on R+0. Liquid saliva is collected every other day for this entire duration (R+0 to R+14).
In flight, only blood and saliva samples are collected. There is no urine sample requirement for in-flight operations. Subjects perform three sessions in-flight: early, mid and late increment. Each session consists of four liquid saliva collections (performed every other day), with a blood draw and dry book saliva sample collection occurring on the last day of the liquid saliva collections. A health survey is also completed during a subject’s early and mid-mission sessions. For the late increment session, the final liquid saliva sample, the blood draw and dry book saliva sample collections occur on R-1. Blood samples are required to be returned for ground analysis within 48 hours of collection; therefore, the blood draws must occur in conjunction with a Shuttle or Soyuz flight to ISS.
Operations for this experiment consist of three types of sample collections: blood, urine and saliva. There are two types of saliva samples collected. Liquid saliva samples require the subject to soak a piece of cotton with saliva and place the cotton in a salivette bag. Dry book saliva samples are collected on filter paper bound in a small, specialized book at certain time intervals throughout the collection day. For preflight and postflight baseline data collection only, 24-hour urine collections require the subject to collect all urine starting with the first void of the day and continuing for a full 24-hour period.
Very little hard data exists regarding in-flight adverse medical events and the body’s ability to recover from such events during space flight. Of particular concern are conditions related to immunology; such as allergies, rashes, hypersensitivities, infections and wound healing. The data that does exist is often sequestered due to medical confidentiality. Therefore, in addition to collecting blood, saliva and urine, crewmembers will be requested to complete an immunology health survey.
In July 2002 NASA conducted a comprehensive immune assessment on the Haughton-Mars Project field team members. This project validated sampling methods, and laboratory results indicated that changes in immune function and stress hormone in the HMP field participants were similar to those observed in astronauts following space flight. Taken together, these data support the establishment of the HMP as a unique ground-based space flight and planetary exploration test bed that may have significant utility for terrestrial human physiology studies (Crucian et al. 2007).
Building on knowledge gained from ground-base field research, i.e. the HMP, Stowe et al. 2011 performed a study to determine if space flight duration has an effect on the levels of stress hormones. Researchers collected multiple preflight and postflight samples from Shuttle and ISS crewmembers from 2007 onward and found that Shuttle crewmembers on short missions, lasting about 2 weeks, experienced greater initial stress, even prior to launch, than crewmembers leaving for a much longer 6-month tour on board the ISS. After short-duration missions, white blood cell (WBC) counts were elevated and typical stress-induced shifts were observed, and a general immunity assessment confirmed a parallel decrease in immune function. Changes in monocytes, a type of WBC, parameters and defense signaling capacity may also impact overall crewmember immune system health (Crucian et al. 2007). ISS crewmembers, by contrast, did not show increased cortisol stress hormone levels at any time prior to launch, and a plausible explanation is the training, which differs greatly for these astronauts who are prepared mentally for long-duration flights that are psychologically challenging, is much longer and diverse than Shuttle astronauts. Stress hormones returned to preflight levels for both groups after a few days back on Earth. In addition, approximately 50% of the subjects had very high WBC counts which have typically been associated with increased stress hormones at landing, but it is important to note that such elevated values are indicative of infection or disease in otherwise healthy individuals and may mask true infection. Unexpectedly, some subsets of white blood cells did not show normal response to the rise in stress hormones for long-duration crewmembers. Further study is needed to determine if this is a failure of these WBCs to properly respond to acute stress or if the blood production process is altered during long-duration spaceflight. These results agree with prior studies demonstrating the importance of mission duration in the magnitude of these changes. The authors conclude that the current ISS training successfully reduces stress, and interventions employed during this period in which astronauts are most accessible would likely produce the desired effects (Stowe et al. 2011).
NASA Image: ISS030E257695